Cargando…
Micafungin in Premature and Non-premature Infants: A Systematic Review of 9 Clinical Trials
BACKGROUND: Invasive fungal infections cause excessive morbidity and mortality in premature neonates and severely ill infants. METHODS: Safety and efficacy outcomes of micafungin were compared between prematurely and non-prematurely born infants <2 years of age. Data were obtained from all comple...
Autores principales: | Manzoni, Paolo, Wu, Chunzhang, Tweddle, Lorraine, Roilides, Emmanuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Williams & Wilkins
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196786/ https://www.ncbi.nlm.nih.gov/pubmed/24892849 http://dx.doi.org/10.1097/INF.0000000000000434 |
Ejemplares similares
-
A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis
por: Benjamin, Daniel K., et al.
Publicado: (2018) -
Successful therapy of Candida pulcherrima fungemia in a premature newborn with liposomal amphotericin B and micafungin
por: Mpakosi, Alexandra, et al.
Publicado: (2016) -
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial
por: Roilides, Emmanuel, et al.
Publicado: (2023) -
Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
por: Roilides, Emmanuel, et al.
Publicado: (2020) -
Issues of vaccination in premature infants: an overview
por: Manzoni, Paolo, et al.
Publicado: (2015)